Kurzfassung

Anti-citrullinated protein antibodies (ACPAs) may play a role in the initiation and progression of rheumatoid arthritis. Furthermore, different ACPAs may be associated with different clinical outcomes. In the Adapthera cohort we follow patients with VERA longitudinally collecting clinical data and biomaterials to identify novel biomarkers. The pattern of ACPAs could serve as predictive, prognostic and therapy-related biomarkers.
Objectives: (1) To assess the relationship between changes in...Anti-citrullinated protein antibodies (ACPAs) may play a role in the initiation and progression of rheumatoid arthritis. Furthermore, different ACPAs may be associated with different clinical outcomes. In the Adapthera cohort we follow patients with VERA longitudinally collecting clinical data and biomaterials to identify novel biomarkers. The pattern of ACPAs could serve as predictive, prognostic and therapy-related biomarkers.
Objectives: (1) To assess the relationship between changes in ACPA and disease activity in 100 patients with VERA over time (3 years) with special emphasis on differential effects of medication (abatacept) and
(2) To assess the pattern of citrullinated peptides/proteins in patients with yet unclassified arthritis (UA).
 » weiterlesen» einklappen